Cassava Sciences Announces Positive End-of-Phase 2 Meeting with FDA and Outlines Pivotal Phase 3 Program for Simufilam in Alzheimer’s Disease

NASDAQ Market News

NEXT STORY
Adamis Pharmaceuticals Cleared to Proceed with Human Studies of Tempol for the Treatment of COVID-19
PREV STORY
Gene Panel Market Is Estimated to Reach USD 4.34 Billion by 2025 at CAGR of 12.16% | Market Research Future (MRFR)
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Data from Pivotal Phase 2b Study of Progenics’ AZEDRA® (iobenguane I 131) to be Presented at the North American Neuroendocrine Tumor Society 2017 Annual Symposium

NEW YORK, Oct. 04, 2017 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology ...

author_avatar
NASDAQ Market News

CytomX Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock

author_avatar
NASDAQ Market News

Applied Therapeutics to be Added to NASDAQ Biotechnology Index

author_avatar
NASDAQ Market News